Holocene Advisors
NVCR icon

Holocene Advisors’s NovoCure NVCR Stock Holding History

Holocene Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-18,229
Closed -$236K – 926
2025
Q4 		$236K Buy
+18,229
New +$234K ﹤0.01% 716
2025
Q3 		– Sell
-64,322
Closed -$1.14M – 865
2025
Q2 		$1.14M Buy
64,322
+52,343
+437% +$912K ﹤0.01% 629
2025
Q1 		$213K Sell
11,979
-27,963
-70% -$635K ﹤0.01% 716
2024
Q4 		$1.19M Sell
39,942
-34,306
-46% -$726K ﹤0.01% 643
2024
Q3 		$1.16M Buy
74,248
+22,276
+43% +$404K ﹤0.01% 601
2024
Q2 		$890K Sell
51,972
-117,445
-69% -$2.07M ﹤0.01% 611
2024
Q1 		$2.65M Buy
169,417
+3,919
+2% +$57.6K 0.01% 537
2023
Q4 		$2.47M Sell
165,498
-77,340
-32% -$1.04M 0.01% 496
2023
Q3 		$3.92M Buy
+242,838
New +$7M 0.02% 428
2022
Q2 		– Sell
-21,202
Closed -$1.76M – 944
2022
Q1 		$1.76M Buy
+21,202
New +$1.56M 0.01% 560
2020
Q4 		– Sell
-5,793
Closed -$645K – 813
2020
Q3 		$645K Buy
+5,793
New +$463K ﹤0.01% 546

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return

Holocene Advisors's NVCR Position: Q1 2026 in Review

Holocene Advisors sold out of NovoCure (NVCR) in Q1 2026, closing a stake of 18,229 shares — an estimated $236K sold.

Holocene Advisors first reported a position in NVCR in Q3 2020 and held it in 11 quarters. The position peaked at $3.92M in Q3 2023. 222 funds tracked by Wall St. Rank hold NVCR as of Q1 2026.

  • Holocene Advisors reported no remaining NovoCure position as of Q1 2026 after selling out during the quarter.
  • Holocene Advisors sold 18,229 NovoCure shares in Q1 2026, an estimated $236K.
  • Holocene Advisors first reported a position in NovoCure in Q3 2020 and held it in 11 quarters.
  • Holocene Advisors's NovoCure position peaked at $3.92M in Q3 2023.
  • 222 funds tracked by Wall St. Rank held NovoCure as of Q1 2026.

Based on Holocene Advisors's 13F filing for Q1 2026, filed 15 May 2026.